To validate DLK1 expression, we performed DLK1 IHC across our cohort of ACC metastatic tumors and found 97% (n=28/29) of ACC patients were DLK1+ (mean H-score 147) with H-scores ranging from 10 to 300 (Fig. 1D). This evidence concerns the gene DLK1 and metastatic neoplasm.